Evidence map›Paper›PMID 40276907›Full record

ArticleJournal of movement disorders2025

Safety and Efficacy of Istradefylline in Parkinson's Disease Patients With and Without Preexisting Dyskinesia: Pooled Analysis of 8 Randomized Controlled Trials.

Nobutaka Hattori, Lawrence Elmer, Stuart H Isaacson, Rajesh Pahwa, Olivier Rascol, Kapil Sethi, Fabrizio Stocchi, Yu Nakajima, Hannah Cummings, Lia Kostiuk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of movement disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Nobutaka HattoriDepartment of Neurology, Juntendo University School of Medicine, Tokyo, Japan.
Lawrence ElmerDepartment of Neurology, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA.
Stuart H IsaacsonParkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, FL, USA.
Rajesh PahwaUniversity of Kansas Medical Center, Kansas City, KS, USA.
Olivier RascolToulouse Parkinson Expert Center, Departments of Neurosciences and Clinical Pharmacology, Centre d'Investigation Clinique de Toulouse CIC1436, NS-Park/FCRIN Network, and NeuroToul COEN Center, University Hospital of Toulouse, INSERM, University of Toulouse III, Toulouse, France.
Kapil SethiMedical College of Georgia, Augusta University, Augusta, GA, USA.
Fabrizio StocchiInstitute for Research and Medical Care, IRCCS San Raffaele, Rome Italy.
Yu NakajimaBiometrics, Kyowa Kirin Co., Ltd., Tokyo, Japan.
Hannah CummingsMedical Affairs, Kyowa Kirin, Inc., Bedminster, NJ, USA.
Lia KostiukMedical Affairs, Kyowa Kirin, Inc., Bedminster, NJ, USA.

Funding

Kyowa Kirin, Inc.
6 · The paper itself

Abstract

objectiveTo evaluate the efficacy of istradefylline in Parkinson's disease patients experiencing motor fluctuations with and without dyskinesia and characterize potential predictors for treatment-emergent dyskinesia with istradefylline.

methodsPooled analysis of 8 phase 2b/3 trials of istradefylline (20 or 40 mg/day) versus placebo.

resultsData from 2,719 patients, 56% of whom presented with baseline dyskinesia, were analyzed post hoc. The presence of baseline dyskinesia did not affect the mean decrease in "OFF" time with dyskinesia, increase in "ON" time without troublesome dyskinesia, or improvement in the Unified Parkinson's Disease Rating Scale motor score associated with istradefylline treatment. Dyskinesia was reported in 17% of patients receiving istradefylline, with higher rates for women (21%), patients with a BMI <18.5 kg/m2 (22%), and patients receiving catechol-o-methyltransferase inhibitors plus dopamine agonists (22%) and monoamine oxidase B inhibitors (25%).

conclusionIstradefylline treatment resulted in greater reductions in total "OFF" hours/day and increases in "ON" time without troublesome dyskinesia than did placebo, regardless of the presence or absence of preexisting dyskinesia.

Indexed as

Adenosine A2 receptor antagonistDyskinesiaIstradefyllineParkinson’s disease

Identifiers

PMID40276907
PMCPMC12301946

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.